## ERRATUM

**Open Access** 



Erratum to: Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis

Cheryl McQuire<sup>1</sup>, Angela Hassiotis<sup>2\*</sup>, Bronwyn Harrison<sup>1</sup> and Stephen Pilling<sup>3</sup>

After the publication of the original article [1] in BMC Psychiatry it was brought to our attention that Figs. 3, 4, 5, 6, 7, 8 and 9 were ordered incorrectly. Please find the correct order of the figures and citations below.

#### Author details

<sup>1</sup>National Collaborating Centre for Mental Health, Royal College of Psychiatrists, 21 Prescot Street, London E1 8BB, UK. <sup>2</sup>Division of Psychiatry, University College London, Charles Bell House, 1st and 2nd Floor, 67-73 Riding House Street, London W1W 7EJ, UK. <sup>3</sup>Centre for Outcomes Research and Effectiveness, University College London, 1-19 Torrington Place, London WC1E 7HB, UK.

### Received: 15 December 2015 Accepted: 17 December 2015 Published online: 07 January 2016

#### Reference

 McQuire C, Hassiotis A, Harrison B, Pilling S. Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis. BMC Psychiatry. 2015;15:303.

<sup>2</sup>Division of Psychiatry, University College London, Charles Bell House, 1st

and 2nd Floor, 67-73 Riding House Street, London W1W 7EJ, UK

Full list of author information is available at the end of the article

# Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit



**BioMed** Central

\* Correspondence: a.hassiotis@ucl.ac.uk

© 2016 McQuire et al. **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

	Antipsychotic	Placebo			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean SD Total	Mean SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.1.1 Risperidone: o	challenging behaviour e	ndpoint score				
Shea 2004	6.67 6.21 21	21.6 14.5	20	16.9%	-1.32 [-2.01, -0.64]	
Aman 2002	15.14 8.98 22	27.69 11	35	22.2%	-1.20 [-1.79, -0.62]	
Snyder 2002	16.17 10.67 24	24.5 14.23	34	25.3%	-0.64 [-1.17, -0.10]	
RUPP 2002	11.3 7.4 49			35.6%	-1.23 [-1.66, -0.80]	
Subtotal (95% CI)	116		141	100.0%	-1.09 [-1.39, -0.79]	◆
Heterogeneity: Tau <sup>a</sup>	= 0.02; Chi# = 3.75, df =	3 (P = 0.29); I <sup>a</sup> =	20%			
Test for overall effect	t: Z = 7.07 (P < 0.00001)					
1.1.2 Risperidone: o	challenging behaviour c	hange from bas	seline sc	ore		_
Kent 2013	-12.4 6.52 31			100.0%	-0.98 [-1.49, -0.47]	
Subtotal (95% CI)	31		35	100.0%	-0.98 [-1.49, -0.47]	◆
Heterogeneity: Not a						
Test for overall effec	t Z = 3.75 (P = 0.0002)					
1.1.3 Aripiprazole: o	challenging behaviour c	hange from bas	seline sc	ore		
Owen 2009	-12.9 9.5 46	-5 9.8	49	38.7%	-0.81 [-1.23, -0.39]	
Marcus 2009	-13.33 9.24 164			61.3%	-0.52 [-0.85, -0.20]	
Subtotal (95% CI)	210		98	100.0%	-0.64 [-0.91, -0.36]	◆ 1
	= 0.00; Chi# = 1.13, df =		12%			
Test for overall effect	t Z = 4.54 (P < 0.00001)					
						-4 -2 0 2 4
						Favours antipsychotic Favours placebo
ffact of risparidana an	d arininrazolo or	, challongi	na ha	havio	ur in childron wi	th intellectual disabilities
nect of hspendone an	u anpipiazole ol	i challengi	ng be	: I I a VIO	ui in children wi	th intellectual disabilities











